Radiolabeling of anti-CD45 immunoglobulin and methods of use thereof
AssigneeActinium Pharmaceuticals, Inc.
InventorsDale Ludwig, Sandesh Seth
Life of this patent
Estimating the term…
Abstract
Compositions and methods useful for the treatment of hemoglobinopathies and hematological diseases are disclosed herein. The compositions include an actinium-225 labeled anti-CD45 antibody (BC8) formulated as a single patient dose that is wholly deliverable to a patient in a single dose. The actinium-225 labeled anti-CD45 may be administered alone or in combination with additional therapeutic agents, such as other immunotherapeutics or a radiosensitizing agent, or additional therapeutic interventions, such as bone marrow transplant or adoptive cell therapies.
Claims23
A method for treating a hemoglobinopathy or a hematological disease or disorder comprising:
- administering a composition comprising an effective amount of a population of anti-CD45 antibodies comprising light chain complementarity determining regions having the amino acid sequences set forth in SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5, and heavy chain complementarity determining regions having the amino acid sequence set forth in SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8,
- wherein the population of anti-CD45 antibodies comprises antibodies wherein the amino acid at position 141 of the heavy chain (relative to the N-terminal amino acid) is ASP and antibodies wherein the amino acid at position 141 of the heavy chain (relative to the N-terminal amino acid) is ASN,
- wherein a fraction of the population of anti-CD45 antibodies is radiolabeled with actinium-225 and the remaining fraction is not radiolabeled,
- wherein the fraction of the population of anti-CD45 antibodies radiolabeled with actinium-225 consists essentially of the conjugate of anti-CD45 monoclonal antibody with p-SCN-Bn-DOTA comprising chelated actinium-225, and
- wherein the effective amount is administered as a single dose.
Dependencies are inferred from the claim text.